Shareholder Alert: The Ademi Firm Continues to Investigate Whether CARGO Therapeutics, Inc. is Obtaining a Fair Price for its Public Shareholders

MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating CARGO (NASDAQ: CRGX) for possible breaches of fiduciary duty and other violations of law in its transaction with Concentra Biosciences. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, shareholders of CARGO will receive $4.379 in cash per share, plus one non-transferable continge.

Business Wire • Sep 15, 2025

Shareholder Alert: The Ademi Firm Investigates Whether CARGO Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders

MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating CARGO (NASDAQ: CRGX) for possible breaches of fiduciary duty and other violations of law in its transaction with Concentra Biosciences. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, shareholders of CARGO will receive $4.379 in cash per share, plus one non-transferable continge.

Business Wire • Aug 8, 2025

URGENT: The M&A Class Action Firm Launches Legal Inquiry for the Merger - CRGX, HSON, BRZH, and ENZB

NEW YORK , July 25, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde  with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating CARGO Therapeutics, Inc. (NASDAQ: CRGX) related to its sale to Concentra Biosciences, LLC for $4.379 in cash per CARGO share, plus one non-transferable contingent value right, representing the right to receive: (i) 100% of the closing net cash of CARGO in excess of $217.5 million; and (ii) 80% of the net proceeds from the sale, license, or other disposition of either (a) CRG-022, a CDRR CAR T-cell therapy, or (b) CRG-023, a CD19/CD20/CD22 tri-specific CAR T therapy, or (c) the Allogeneic Platform, that occurs within 2 years following the closing.

PRNewsWire • Jul 25, 2025

CARGO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of CARGO Therapeutics, Inc. - CRGX

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of CARGO Therapeutics, Inc. (NasdaqGS: CRGX) to Concentra Biosciences, LLC. Under the terms of the proposed transaction, Concentra will acquire CARGO for $4.379 in cash per share, plus one non-transferable contingent value right, representing the right to receive: (i) 100% of the closing net cash of CA.

Business Wire • Jul 25, 2025

$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of CARGO Therapeutics, Inc. (NASDAQ: CRGX)

NEW YORK, July 09, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating CARGO Therapeutics, Inc. (NASDAQ: CRGX ) related to its sale to Concentra Biosciences, LLC for $4.379 in cash per CARGO share, plus one non-transferable contingent value right, representing the right to receive: (i) 100% of the closing net cash of CARGO in excess of $217.5 million; and (ii) 80% of the net proceeds from the sale, license, or other disposition of either (a) CRG-022, a CDRR CAR T-cell therapy, or (b) CRG-023, a CD19/CD20/CD22 tri-specific CAR T therapy, or (c) the Allogeneic Platform, that occurs within 2 years following the closing. Is it a fair deal?

GlobeNewsWire • Jul 9, 2025

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CRGX and WNS on Behalf of Shareholders

NEW YORK, July 09, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

GlobeNewsWire • Jul 9, 2025

CARGO Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $4.379 in Cash per Share Plus a Contingent Value Right

SAN CARLOS, Calif., July 08, 2025 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (“CARGO” or the “Company”) (NASDAQ: CRGX), a biotechnology company that has focused on developing CAR T-cell therapies, today announced that it has entered into a definitive merger agreement (the “Merger Agreement”) with Concentra Biosciences, LLC (“Concentra”), whereby Concentra will acquire CARGO for $4.379 in cash per share of CARGO common stock, par value $0.001 per share (“CARGO Common Stock”), plus one non-transferable contingent value right (“CVR”), which represents the right to receive: (i) 100% of the closing net cash of CARGO in excess of $217.5 million; and (ii) 80% of any net proceeds received within two years following closing from any disposition of certain of CARGO's product candidates that occurs within two years following closing, each pursuant to a contingent value rights agreement (the “CVR Agreement”).

GlobeNewsWire • Jul 8, 2025

Shareholder Alert: The Ademi Firm investigates whether CARGO Therapeutics, Inc. is obtaining a Fair Price for its Public Shareholders

MILWAUKEE , July 8, 2025 /PRNewswire/ -- The Ademi Firm is investigating CARGO (NASDAQ: CRGX) for possible breaches of fiduciary duty and other violations of law in its transaction with Concentra Biosciences. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995.

PRNewsWire • Jul 8, 2025

CRGX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of CARGO Therapeutics, Inc. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of CARGO Therapeutics, Inc. (NASDAQ: CRGX) to Concentra Biosciences, LLC is fair to CARGO shareholders. Under the terms of the proposed transaction, Concentra will acquire CARGO for $4.379 in cash per share, plus one non-transferable contingent value right, representing the right to receive: (i) 100% of the closing net cash of CARGO in excess of $217.5 million; and (ii) 80% of any net pro.

Business Wire • Jul 8, 2025

CARGO Therapeutics Provides Corporate Update

- Development of CRG-023 and allogeneic platform suspended; further reduction in force (RIF) of approximately 90% to preserve cash and maximize shareholder value - - CARGO had cash, cash equivalents and marketable securities of $368.1 million as of December 31, 2024 - - Anup Radhakrishnan appointed as interim CEO to pursue reverse merger or other business combination - SAN CARLOS, Calif., March 18, 2025 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (Nasdaq: CRGX) today provided an update regarding its ongoing evaluation of strategic options following the discontinuation of FIRCE-1, a Phase 2 study of firicabtagene autoleucel (firi-cel).

GlobeNewsWire • Mar 18, 2025